Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Armata Pharmaceuticals, Inc. (ARMP)

Armata Receives FDA Breakthrough Therapy Designation for AP-SA02

Positive Impact 3 of 5 legal/regulatory Written later

The FDA granted Breakthrough Therapy designation to Armata's AP-SA02, an intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia. The company says the designation is intended to expedite review and that AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, but the filing discloses no revenue, earnings or financing figures.

Key points

  • FDA granted Breakthrough Therapy designation to AP-SA02 for complicated bacteremia caused by MSSA or MRSA, announced September 14, 2026.
  • AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations.
  • In the Phase 1b/2a diSArm study, 100% of AP-SA02 patients maintained clinical response without relapse at 28 days after completion of BAT, compared with 75% on placebo plus BAT.
  • The company plans a Phase 3 superiority study, anticipated to start in the second half of 2026.

The filing

CompanyArmata Pharmaceuticals, Inc. (ARMP)
Form8-K, current report
Filed with the SECSep 14, 2026, 7:12 AM ET
Accession number0001104659-26-107253

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.